Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Marta Guzman"'
Autor:
Laura Pascual‐Reguant, Queralt Serra‐Camprubí, Debayan Datta, Damiano Cianferoni, Savvas Kourtis, Antoni Gañez‐Zapater, Chiara Cannatá, Lorena Espinar, Jessica Querol, Laura García‐López, Sara Musa‐Afaneh, Maria Guirola, Anestis Gkanogiannis, Andrea Miró Canturri, Marta Guzman, Olga Rodríguez, Andrea Herencia‐Ropero, Joaquin Arribas, Violeta Serra, Luis Serrano, Tian V Tian, Sandra Peiró, Sara Sdelci
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 12, Pp 1-23 (2023)
Abstract Triple‐negative breast cancer (TNBC) often develops resistance to single‐agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergis
Externí odkaz:
https://doaj.org/article/a9ac7e4ea8d342f3a90f379ec5eb682e
Autor:
Laura Soucek, Jonathan R. Whitfield, Lars-Gunnar Larsson, Violeta Serra, Joaquín Arribas, Marta Guzman, Marta Escorihuela, Antonio Luque-García, Loay Mahmoud, Mohammad Alzrigat, Miguel Ángel Morcillo, Sergio López-Estévez, Jastrinjan Kaur, Virginia Castillo Cano, Sílvia Casacuberta-Serra, Génesis Martín-Fernández, Erika Serrano, Sandra Martínez-Martín, Laia Foradada, Mariano F. Zacarías-Fluck, Fabio Giuntini, Toni Jauset, Marie-Eve Beaulieu, Daniel Massó-Vallés
MYC's role in promoting tumorigenesis is beyond doubt, but its function in the metastatic process is still controversial. Omomyc is a MYC dominant negative that has shown potent antitumor activity in multiple cancer cell lines and mouse models, regar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::905558f9f525b058b676fca6f1e89484
https://doi.org/10.1158/2767-9764.c.6550557
https://doi.org/10.1158/2767-9764.c.6550557
Autor:
José Baselga, Claudia Aura, José Jimenez, Ludmila Prudkin, Varenka Rodriguez, Kip A. West, Kelly L. Slocum, Alice R. Lim, Olga Rodriguez, Marta Guzman, Emmanuel Normant, Violeta Serra, Maurizio Scaltriti
Supplementary Figure 3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f6adafe9a431b9bcbd2909aa5581fe
https://doi.org/10.1158/1535-7163.22497190
https://doi.org/10.1158/1535-7163.22497190
Autor:
José Baselga, Claudia Aura, José Jimenez, Ludmila Prudkin, Varenka Rodriguez, Kip A. West, Kelly L. Slocum, Alice R. Lim, Olga Rodriguez, Marta Guzman, Emmanuel Normant, Violeta Serra, Maurizio Scaltriti
Supplementary Figure 1 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bad67847ef5041dbe893b8aa7bc98cb
https://doi.org/10.1158/1535-7163.22497196
https://doi.org/10.1158/1535-7163.22497196
Autor:
José Baselga, Claudia Aura, José Jimenez, Ludmila Prudkin, Varenka Rodriguez, Kip A. West, Kelly L. Slocum, Alice R. Lim, Olga Rodriguez, Marta Guzman, Emmanuel Normant, Violeta Serra, Maurizio Scaltriti
Supplementary Figure 2 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57460a9bcd3d82a689dda3fd312a969e
https://doi.org/10.1158/1535-7163.22497193
https://doi.org/10.1158/1535-7163.22497193
Autor:
José Baselga, Claudia Aura, José Jimenez, Ludmila Prudkin, Varenka Rodriguez, Kip A. West, Kelly L. Slocum, Alice R. Lim, Olga Rodriguez, Marta Guzman, Emmanuel Normant, Violeta Serra, Maurizio Scaltriti
Supplementary Figure Legends 1-3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e8af4d7bd1c867b5a33e4eca1792778
https://doi.org/10.1158/1535-7163.22497187.v1
https://doi.org/10.1158/1535-7163.22497187.v1
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Supplementary Figure from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4129939bd7a944921efb38cdb3344eaf
https://doi.org/10.1158/1078-0432.22489313.v1
https://doi.org/10.1158/1078-0432.22489313.v1
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Supplementary Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddb28e2b040877b2021a52cb106bd7a
https://doi.org/10.1158/1078-0432.22489322
https://doi.org/10.1158/1078-0432.22489322
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Purpose:PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292ea7f6a2f41a4ddcc686cb101c0beb
https://doi.org/10.1158/1078-0432.c.6532931.v1
https://doi.org/10.1158/1078-0432.c.6532931.v1
Autor:
José Baselga, Premal Patel, Josep Tabernero, Andrés Cervantes, Desamparados Roda, Cristina Saura, Mark R. Lackner, Vanitha Ramakrishnan, Garret Hampton, Matthew Wongchenko, Jenny Q. Wu, Marie-Claire Wagle, Yuanyuan Xiao, Michelle Nannini, Deepak Sampath, Marta Guzman, Olga Rodríguez, Sumati Murli, Maurizio Scaltriti, Ludmila Prudkin, Violeta Serra, Yibing Yan
XLS file 38K, Single-biomarker tumor growth inhibition projection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::236e0d5d5c98f2e6a33a1bd18cb51431
https://doi.org/10.1158/1078-0432.22447065
https://doi.org/10.1158/1078-0432.22447065